Sigilon Therapeutics

About:

Sigilon Therapeutics is a biotech company that specializes in creating immune-privileged products for treating acute and chronic diseases.

Website: http://sigilon.com

Twitter/X: Sigilon_Inc

Top Investors: BlackRock, Eli Lilly, Flagship Pioneering, CPP Investments, DM Capital

Description:

Sigilon Therapeutics is to create immune-protected, engineered human cells that restore normal physiology in a wide range of diseases without generating fibrosis or immune rejection, liberating patients from challenges associated with serious chronic diseases. To address these therapy problems, Sigilon is developing its Shielded Living TherapeuticsTM platform. Sigilon is designing product candidates to provide a wide range of functions or therapeutic molecules that may be missing or deficient in the body, leveraging advances in cell differentiation and engineering, as well as cutting-edge innovations in its proprietary biocompatible materials—potentially resulting in functional cures for patients with a wide range of acute and chronic diseases.